Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma

References

• Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93–11. doi:10.1016/j.eururo.2016.02.029.
   PubMed Web of Science ®Google Scholar
• de Peralta-Venturina M, Moch H, Amin M, Tamboli P, Hailemariam S, Mihatsch M, Javidan J, Stricker H, Ro JY, Amin MB. Sarcomatoid differentiation in renal cell carcinoma. Am J Surg Pathol. 2001;25(3). doi:10.1097/00000478-200103000-00001.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B, Liu L-F, Leng N, Abbas AR, et al. Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade. Cancer Cell. 2020;38(6):803–17.e4. doi:10.1016/j.ccell.2020.10.011.
   PubMed Web of Science ®Google Scholar
• Zhang T, Gong J, Maia MC, Pal SK. Systemic therapy for non-clear cell renal cell carcinoma. Am Soc Clin Oncol Educ Book. 2017;37:337–42. doi:10.1200/EDBK_175572.
   PubMedGoogle Scholar
• Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, Garcia JA, Vaishampayan UN, Picus J, Hawkins RE, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomized phase 2 trial. Lancet Oncol. 2016;17:(3):378–88. doi:10.1016/S1470-2045(15)00515-X.
   PubMed Web of Science ®Google Scholar
• Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, Wang X, Qiao W, Dubauskas Lim Z, Tamboli P, et al. Everolimus versus Sunitinib prospective evaluation in metastatic non–clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69(5):866–74. doi:10.1016/j.eururo.2015.10.049.
   PubMed Web of Science ®Google Scholar
• Fernández-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, et al. A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol. 2017;71(3):426–36. doi:10.1016/j.eururo.2016.11.020.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Heng DYC, Lee JL, Cancel M, Verheijen RB, Mellemgaard A, Ottesen LH, Frigault MM, L’Hernault A, Szijgyarto Z, et al. Efficacy of Savolitinib vs Sunitinib in patients with MET -driven papillary renal cell carcinoma. JAMA Oncol. 2020;6(8):1247–55. doi:10.1001/jamaoncol.2020.2218.
   PubMed Web of Science ®Google Scholar
• Pal SK, Tangen C, Thompson IM Jr, Balzer-Haas N, George DJ, Heng DYC, Shuch B, Stein M, Tretiakova M, Humphrey P, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. doi:10.1016/S0140-6736(21)00152-5.
   PubMed Web of Science ®Google Scholar
• Choueiri TK, Fay AP, Gray KP, Callea M, Ho TH, Albiges L, Bellmunt J, Song J, Carvo I, Lampron M, et al. PD-L1 expression in non-clear-cell renal cell carcinoma. Ann Oncol. 2014;25(11):2178e84. doi:10.1093/annonc/mdu445.
   Web of Science ®Google Scholar
• Zarrabi K, Walzer E, Zibelman M. Immune checkpoint inhibition in advanced non-clear cell renal cell carcinoma: leveraging success from clear cell histology into new opportunities. Cancers (Basel). 2021;13(15):3652. doi:10.3390/cancers13153652.
   PubMed Web of Science ®Google Scholar
• Garje R, Elhag D, Yasin HA, Acharya L, Vaena D, Dahmoush L. Comprehensive review of chromophobe renal cell carcinoma. Crit Rev Oncol Hematol. 2021;160:103287. doi:10.1016/j.critrevonc.2021.103287.
   PubMed Web of Science ®Google Scholar
• Rizzo M, Pezzicoli G, Santoni M, Caliò A, Martignoni G, Porta C. MiT translocation renal cell carcinoma: a review of the literature from molecular characterization to clinical management. Biochim Biophys Acta Rev Cancer. 2022;1877(6):188823. doi:10.1016/j.bbcan.2022.188823.
   PubMed Web of Science ®Google Scholar
• Tretiakova MS. Chameleon TFE3-translocation RCC and how gene partners can change morphology: accurate diagnosis using contemporary modalities. Adv Anat Pathol. 2022;29(3):131–40. doi:10.1097/PAP.0000000000000332.
   PubMed Web of Science ®Google Scholar
• Bakouny Z, Sadagopan A, Ravi P, Metaferia NY, Li J, AbuHammad S, Tang S, Denize T, Garner ER, Gao X, et al. Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Rep. 2022;38(1):110190. doi:10.1016/j.celrep.2021.110190.
   PubMed Web of Science ®Google Scholar
• Sun G, Chen J, Liang J, Yin X, Zhang M, Yao J, He N, Armstrong CM, Zheng L, Zhang X, et al. Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. Nat Commun. 2021;12(1):5262. doi:10.1038/s41467-021-25618-z.
   PubMed Web of Science ®Google Scholar
• Sui W, Matulay JT, Robins DJ, James MB, Onyeji IC, RoyChoudhury A, Wenske S, DeCastro GJ. Collecting duct carcinoma of the kidney: disease characteristics and treatment outcomes from the National Cancer Database. Urol Oncol. 2017;35: 540 e513–540 e518. doi:10.1016/j.urolonc.2017.04.010.
   PubMed Web of Science ®Google Scholar
• Bakouny Z, Braun DA, Shukla SA, Pan W, Gao X, Hou Y, Flaifel A, Tang S, Bosma-Moody A, He MX, et al. Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma. Nat Commun. 2021;12(1):808. doi:10.1038/s41467-021-21068-9.
   PubMed Web of Science ®Google Scholar
• Iacovelli R, Ciccarese C, Bria E, Bracarda S, Porta C, Procopio G, Tortora G. Patients with sarcomatoid renal cell carcinoma – re-defining the first-line of treatment: a meta-analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer. 2020;136:195–203. doi:10.1016/j.ejca.2020.06.008.
   PubMed Web of Science ®Google Scholar
• Keskin SK, Msaouel P, Hess KR, Yu K-J, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, et al. Outcomes of patients with renal cell carcinoma and sarcomatoid dedifferentiation treated with nephrectomy and systemic therapies: comparison between the cytokine and targeted therapy eras. J Urol. 2017;198(3):530–37. doi:10.1016/j.juro.2017.04.067.
   PubMed Web of Science ®Google Scholar
• Powles T, Albiges L, Bex A, Procopio G, Porta C, Schmidinger M, Suarez C, De Velasco G. eUpdate – renal cell carcinoma treatment recommendations. Published 2021 Sep 28.
   Google Scholar
• Pal SK, Uzzo R, Karam JA, Master VA, Donskov F, Suarez C, Albiges L, Rini B, Tomita Y, Kann AG, et al. Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial. Lancet. 2022;400(10358):1103–16. doi:10.1016/S0140-6736(22)01658-0.
   PubMed Web of Science ®Google Scholar
• Noguchi G, Tsutsumi S, Yasui M, Ohtake S, Umemoto S, Nakaigawa N, Yao M, Kishida T. Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report. BMC Urol. 2018;18(1):26. doi:10.1186/s12894-018-0339-2.
   PubMedGoogle Scholar
• Rouvinov K, Osyntsov L, Shaco-Levy R, Baram N, Ariad S, Mermershtain W. Rapid response to Nivolumab in a patient with Sarcomatoid transformation of chromophobe renal cell carcinoma. Clin Genitourin Cancer. 2017;15(6):e1127–30. doi:10.1016/j.clgc.2017.05.028.
   PubMed Web of Science ®Google Scholar
• Han SY, Jahagirdar BN, Dudek AZ. Two malignancies with differential responses to immune checkpoint inhibitors: a case report. Anticancer Res. 2020;40(5):2821–26. doi:10.21873/anticanres.14255.
   PubMed Web of Science ®Google Scholar
• Marcon J, DiNatale RG, Sanchez A, Kotecha RR, Gupta S, Kuo F, Makarov V, Sandhu A, Mano R, Silagy AW, et al. Comprehensive genomic analysis of translocation renal cell carcinoma reveals copy-number variations as drivers of disease progression. Clin Cancer Res. 2020;26(14):3629–40. doi:10.1158/1078-0432.CCR-19-3283.
   PubMed Web of Science ®Google Scholar
• Zhao J, Dai K, Xie J, Fang C, Chen N, Dai J, Xu D. Case report: clinical complete response of advanced renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion by treated by camrelizumab and axitinib: a rare case report. Front Pharmacol. 2022;13:927299. doi:10.3389/fphar.2022.927299.
   PubMed Web of Science ®Google Scholar
• Yan X, Zhou L, Li S, Wu X, Cui C, Chi Z, Si L, Kong Y, Tang B, Li C, et al. Systemic therapy in patients with metastatic Xp11.2 translocation renal cell carcinoma. Clin Genitourin Cancer. 2022;20(4):354–62. doi:10.1016/j.clgc.2022.03.005.
   PubMed Web of Science ®Google Scholar
• Masago T, Kobayakawa S, Ohtani Y, Taniguchi K, Naka T, Kuroda N, Takahashi C, Isoyama T, Sejima T. Xp11.2 translocation renal cell carcinoma with TFE3 gene fusion in the elderly: case report and literature review. Int Cancer Conf J. 2020;9(4):182–86. doi:10.1007/s13691-020-00430-6.
   PubMed Web of Science ®Google Scholar
• Oudard S, Banu E, Vieillefond A, Fournier L, Priou F, Medioni J, Banu A, Duclos B, Rolland F, Escudier B, et al. Prospective multicenter phase II study of gemcitabine plus platinum salt for metastatic collecting duct carcinoma: results of a GETUG (Groupe d’Etudes des Tumeurs Uro-Génitales) study. J Urol. 2007;177:1698–702. doi:10.1016/j.juro.2007.01.063.
   PubMed Web of Science ®Google Scholar
• Procopio G, Sepe P, Claps M, Buti S, Colecchia M, Giannatempo P, Guadalupi V, Mariani L, Lalli L, Fucà G, et al. Cabozantinib as first-line treatment in patients with metastatic collecting duct renal cell carcinoma: results of the BONSAI trial for the Italian Network for Research in Urologic-Oncology (Meet-URO 2 Study). JAMA Oncol. 2022;8(6):910–13. doi:10.1001/jamaoncol.2022.0238.
   PubMed Web of Science ®Google Scholar
• Mee Guillaume Z, Colomba E, Thouvenin J, Saldana C, Campedel L, Dumond C, Laguerre B, Maillet D, Vicier C, Rolland F, et al. Metastatic renal medullary and collecting duct carcinoma in the era of antiangiogenic and immune checkpoint inhibitors: a multicentric retrospective study. Cancers (Basel). 2022;14(7):1678. doi:10.3390/cancers14071678.
   PubMed Web of Science ®Google Scholar
• Mizutani K, Horie K, Nagai S, Tsuchiya T, Saigo C, Kobayashi K, Miyazaki T, Deguchi T. Response to nivolumab in metastatic collecting duct carcinoma expressing PD‑L1: a case report. Mol Clin Oncol. 2017;7(6):988–90. doi:10.3892/mco.2017.1449.
   PubMed Web of Science ®Google Scholar
• Yasuoka S, Hamasaki T, Kuribayashi E, Nagasawa M, Kawaguchi T, Nagashima Y, Kondo Y. Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: a case report. Medicine. 2018;97:e13173. doi:10.1097/MD.0000000000013173.
   PubMed Web of Science ®Google Scholar
• Rimar KJ, Meeks JJ, Kuzel TM. Anti-programmed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma. Clin Genitourin Cancer. 2016;14:e431–34. doi:10.1016/j.clgc.2016.02.013.
   PubMed Web of Science ®Google Scholar
• Buti S, Bersanelli M, Mazzaschi G, Cattrini C, Brunelli M, Di Maio M. Can we identify a preferred first-line strategy for sarcomatoid renal cell carcinoma? A network meta-analysis. Immunotherapy. 2022;14(2):145–53. doi:10.2217/imt-2021-0157.
   PubMed Web of Science ®Google Scholar
• Powles T, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Gurney H, Chang Y-H, Lee JL, et al. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(9):1133–44. doi:10.1016/S1470-2045(22)00487-9.
   PubMed Web of Science ®Google Scholar